Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Eyes On With Lenovo's ThinkVision 27 Glasses-Free 3D Monitor
Nasa launches Psyche mission to study an ancient metal asteroid
Musk's X disabled feature for reporting electoral misinformation - researcher
Airbus Ventures Invests in Venus Aerospace
System Initiative Heralds the Second Wave of DevOps with a New Collaborative Power Tool That Rebuilds DevOps from the Ground Up
How tech could turn our homes into renewable energy power stations
Iteris Awarded Contract for Seminole County Traffic Signal Retiming Program
This refurbished MacBook Pro is only $256